Morgan Stanley Nuvectis Pharma, Inc. Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
A detailed history of Morgan Stanley transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,319 shares of NVCT stock, worth $17,183. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,319
Previous 2,348
1.24%
Holding current value
$17,183
Previous $14,000
14.29%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding NVCT
# of Institutions
29Shares Held
1.93MCall Options Held
0Put Options Held
0-
Ronit Capital LLP563KShares$4.17 Million5.37% of portfolio
-
Baldwin Brothers LLC356KShares$2.64 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA325KShares$2.41 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0125KShares$923,0710.0% of portfolio
-
Black Rock Inc. New York, NY83.4KShares$618,0820.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $109M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...